Allogene Therapeutics, Inc.
ALLO
13 insider filings · Latest: Apr 21, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 21, 2024 | Oct 21 8:05 PM | Parker Geoffrey M. | Proposed Sale | 36,404 | $2.84 | $103.5K | — | View → |
| Aug 21, 2024 | Aug 21 8:18 PM | Douglas Earl Martin | Proposed Sale | 28,310 | $2.79 | $78.8K | — | View → |
← Previous
Page 3 of 3
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Feb 4 10:20 PM | Benjamin Machinas BeneskiSVP, Chief Technical Officer | Grant/Award | 479,477 | $1.87 | 105,720(D) | View → |
| Feb 2, 2026 | Feb 4 10:18 PM | Chang David DDirector, President and CEO | Grant/Award | 1,780,517 | $1.87 | 392,586(D) | View → |
| Feb 2, 2026 | Feb 4 10:16 PM | Geoffrey M. ParkerCHIEF FINANCIAL OFFICER | Grant/Award | 691,552 | $1.87 | 152,480(D) | View → |
| Feb 2, 2026 | Feb 4 10:12 PM | Earl Martin DouglasSVP, General Counsel | Grant/Award | 691,552 | $1.87 | 152,480(D) | View → |
| Feb 2, 2026 | Feb 4 10:09 PM | Annie YoshiyamaSVP, Finance | Grant/Award | 230,518 | $1.87 | 50,827(D) | View → |
| Feb 2, 2026 | Feb 4 10:07 PM | Zachary RobertsEVP of R&D | Grant/Award | 922,070 | $1.87 | 203,307(D) | View → |
| Feb 2, 2026 | Feb 4 10:04 PM | Arie BelldegrunDirector | Grant/Award | 1,192,946 | $1.87 | 263,033(D) | View → |